Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Closer Look: Dr. Reddy’s Sees Global Leadership In Biosimilars Via Merck Serono Deal

This article was originally published in PharmAsia News

Executive Summary

Dr. Reddy’s CEO spoke with PharmAsia News to discuss the carefully crafted deal.

Advertisement

Related Content

With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim
India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10
Partnering Better Than Solo Play For Biosimilars, Says Dr. Reddy's CEO; Limited Growth In Generics Will Lead To Moves For Innovative Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC081326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel